The US Food and Drug Administration has approved Protein Sciences Corporation’s
vaccine Flublok for the prevention of seasonal influenza in adults 18 to 49
years of age. Diamyd Medical holds about 8 percent of the shares in Protein
Sciences Corporation.
Flublok is a recombinant protein-based seasonal influenza vaccine and the first
influenza vaccine manufactured using recombinant technology that has received
marketing approval by the FDA. Protein Sciences Corporation is planning to have
a limited launch of the product in February 2013 with the full launch occurring
in time for the 2013/14 influenza season. More information can be found at
www.proteinsciences.com or www.flublok.com.
About Protein Sciences Corporation
Protein Sciences Corporation, founded in 1983, is a privately held biotechnology
company located in Meriden, Connecticut, USA. The Company focuses on the
development and commercialization of recombinant vaccines and biopharmaceuticals
based on the Company’s patented manufacturing platform BEVS (Baculovirus
Expression Vector System). Protein Sciences’ lead product candidates are Flublok
against seasonal influenza, and Panblok against pandemic influenza.
Protein Sciences is one of only a few companies in the world to develop
recombinant vaccines produced in non-mammalian cells using genetically modified
baculovirus. Some advantages compared to traditional vaccine manufacturing are
that it requires less lead time to manufacture, the products are not produced in
eggs and therefore do not contain egg derivatives, and the manufacturing does
not require the use of live influenza virus, thimerosal or antibiotics.
Protein Sciences also partners with select companies on product development and
manufacturing, and sells proteins for research purposes. The Company is for
example the contract manufacturer of the active ingredient GAD for Diamyd
Medical’s antigen-based diabetes therapy Diamyd®.
Diamyd Medical holds about 8 percent of the shares in Protein Sciences
Corporation. On August 31, 2012, the carrying amount of this holding was MSEK
28.4.
For more information, please contact:
Peter Zerhouni, President and CEO Diamyd Medical AB
Phone: +46 8 661 00 26. E-mail: press@diamyd.com
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of pharmaceutical
development. Diamyd Medical is headquartered in Stockholm, Sweden. The Company’s
development project consists of the protein GAD65 for the treatment and
prevention of autoimmune diabetes. A Swedish researcher-initiated Phase II study
is ongoing to evaluate whether GAD65 can prevent type 1 diabetes in children who
are at high risk of developing the disease.
Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation (USA) and
the diagnostics company Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker:
DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC
Markets and the Bank of New York Mellon (PAL). Further information is available
on the Company’s website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities Markets
Act, the Swedish Financial Instruments Trading Act, or the requirements stated
in the listing agreements.
Diamyd Medical AB (publ)
Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no: 556530-1420
